Month: April 2022

Dr. El-Gabry’s extensive leadership experience will be critical to accelerating Akoya’s groundbreaking spatial biomarker research technologies into clinical tools that will impact patient careEhab A. El-Gabry Akoya appoints Ehab A. El-Gabry, MD as Chief Medical OfficerMARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company’s Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya’s strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company’s vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist...

Accomplished business executive and attorney with diverse industry experience including over 20 years in life sciences and pharma with successful track record in value-creating transactions, international business, strategic planning, and mergers and acquisitions of public and private companies EDMONTON, Alberta, April 19, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment of Geneviève Foster to its Board of Directors. Ms. Foster is an established businesswoman, attorney and corporate executive with a background in several industries including life sciences and pharma. Over the course of her career, she has negotiated...

Highlights include plans for $108 Million in Construction Projects, and Increases of over 28% in Sales and $8 Million in Assets FORKED RIVER, N.J., April 19, 2022 (GLOBE NEWSWIRE) — Dream Homes & Development Corporation (OTCPK: DREM)(also known as “DHDC”), announces it filed the Form 10-K annual report for the year ended December 31, 2021 and is now available at DREM 2021 Annual Report. New developments with signed letters of intent, as well as four developments owned by the Company, represent over $108 million in forecasted new home construction projects. This work is anticipated to occur over the next 3-4 years and is in addition to the elevation/renovation division of the business. Management is very positive about these new developments, as well as the cutting-edge construction technologies being employed to create healthier,...

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin®/ Macrilen™in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO, April 19, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that European Patent Office (EPO) has issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin (Ghryvelin®; Macrilen™) for use to diagnose growth hormone deficiency (GHD) in adults. Macimorelin, a ghrelin agonist, is an orally active...

QAPs Supporting Tests That Simultaneously Detect Multiple Respiratory Viruses MISSISSAUGA, Ontario, April 19, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be presenting performance results of its quality assessment products (“QAPs™”) that support molecular-diagnostic (“MDx”) screening-tests for respiratory viruses at two industry congresses – “Labquality Days” in Helsinki, Finland April 20-21, 2022 and “ECCMID 2022” in Lisbon, Portugal, April 23-26, 2022. Labquality Days is an annual international congress focusing on quality in laboratory medicine and medical devices. It is sponsored by Labquality Oy, a well-established Scandinavian clinical-lab proficiency and accreditation authority that is also a Microbix distribution...

EDEN PRAIRIE, Minn., April 19, 2022 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that CEO Jeff Ross will present at the 2022 Cell & Gene Meeting on the Mediterranean. The conference, held this year on April 20 – 22 in Barcelona, Spain, brings together the leading public and private sector companies in the field of advanced therapies. Mr. Ross will deliver his remarks at 3:45 pm CET on April 21st live from the Gaudi 3 Ballroom, which will be simultaneously streamed for virtual attendees. The recordings will also be uploaded into the virtual platform within 24 hours for further on-demand viewing. A short Q&A will follow his presentation. “I am honored to have...